Giovanni Caforio, the former CEO of Bristol Myers Squibb, is set to become the next board chairman of Novartis, which on Tuesday proposed the pharmaceutical industry veteran as its pick to replace Joerg Reinhardt in the role next year.
Reinhardt has served as Novartis’ chair since 2013 and plans to retire when his 12-year term ends in 2025. The appointment of Caforio will be put to Novartis’ shareholders at the company’s annual general meeting. Announcement of the planned succession Tuesday came alongside first quarter earnings that beat Wall Street forecasts.
Caforio spent two decades at Bristol Myers, rising through the ranks to become the company’s CEO in 2015. Under his eight-year tenure as chief, Caforio oversaw a number of major acquisitions, most notably the $74 billion buyout of Celgene that greatly expanded Bristol Myers cancer drug business. More recently, the company agreed to pay $14 billion to acquire brain drug developer Karuna Therapeutics and its closely watched treatment for schizophrenia.
He was replaced as Bristol Myers CEO by Chris Boerner in November.
Reinhardt, meanwhile, started at Sandoz in 1982, joining Novartis via the 1996 merger of Sandoz and Ciba-Geigy. He held several executive positions, including chief operating officer and head of Novartis’ then vaccines and diagnostics division, before he was appointed board chair.
During his time as chair, Novartis switched CEOs and underwent a significant transformation. The drugmaker sold its consumer business to GSK for $13 billion in 2018 and spun out its eye business Alcon.
The company shed its long-held stake in Roche in 2021 and later restructured its workforce and drug pipeline. Last year the company spun out Sandoz, completing the last major step in current CEO Vas Narasimhan’s plan to focus Novartis on high-margin prescription pharmaceuticals.
by Delilah Alvarado
Source: biopharmadive.com
Though Galapagos has undergone plenty of staff shake-ups and strategy revamps in recent years, the company is sticking strong to the CAR-T pivot first unveiled by CEO Paul Stoffels, M.D., following his arrival at the biotech from Johnson & Johnson in early 2022.
The new investment is expected to create more than 500 jobs and significantly strengthen France’s ability to control the production of essential medicines from start to finish, the company stated. According to Sanofi, this plan increases the amount Sanofi has committed to major projects in France since the Covid-19 pandemic to over €3.5 billion.
A tough biotech funding environment and a downturn in COVID-related contracts has weighed heavily on CDMOs of all stripes in recent years. Now, with a new CEO waiting in the wings, Swiss manufacturing juggernaut Lonza is attempting to reassure the market that an industry stabilization is on the horizon.
